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Vaccination induced antibodies to recombinant
avian influenza A virus M2 protein or synthetic
M2e peptide do not bind to the M2 protein on
the virus or virus infected cells
Willem J C Swinkels1, Jeroen Hoeboer1,2, Reina Sikkema2, Lonneke Vervelde2,3 and Ad P Koets1,2*
Abstract
Background: Influenza viruses are characterized by their highly variable surface proteins HA and NA. The third
surface protein M2 is a nearly invariant protein in all Influenza A strains. Despite extensive studies in other animal
models, this study is the first to describe the use of recombinant M2 protein and a peptide coding for the
extracellular part of the M2 protein (M2e) to vaccinate poultry.
Methods: Four groups of layer chickens received a prime-boost vaccination with recombinant M2 protein, M2e, a
tetrameric construct from M2e peptide bound to streptavidin and a control tetrameric construct formulated with
Stimune adjuvant.
Results: We determined the M2-specific antibody (Ab) responses in the serum before vaccination, three weeks after
vaccination and two weeks after booster, at days 21, 42 and 56 of age. The group vaccinated with the M2 protein
in combination with Stimune adjuvant showed a significant Ab response to the complete M2 protein as compared
to the other groups. In addition an increased Ab response to M2e peptide was found in the group vaccinated with
the M2e tetrameric construct. None of the vaccinated animals showed seroconversion to AI in a commercial ELISA.
Finally no Ab’s were found that bound to M2 expressed on in vitro AI infected MDCK cells.
Conclusion: Although Ab’s are formed against the M2 protein and to Streptavidin bound M2e peptide in a
tetrameric conformation these Ab’s do not recognize of M2 on the virus or on infected cells.
Keywords: Influenza, Chicken, M2, Peptide Vaccination
Background
Avian influenza virus (AIV) is mostly classified by its
surface antigens hemagglutinin (HA) and neuraminidase
(NA). Antigenic drift and antigenic shift of these two
immunodominant surface proteins makes it difficult to
construct a universal vaccine [1]. The matrix 2 (M2) sur-
face protein forms an ion channel and is needed for the
release of viral ribonucleoprotein (vRNP) from the
matrix protein 1 (M1) into the cell cytoplasm [2]. The
conserved nature of the extracellular domain of M2
(M2e) makes it an attractive target for developing a vac-
cine to a broad spectrum of influenza A viruses [3-7].
A natural infection renders a limited antibody response
against M2e in both men and mice, probably due to its
low copy number on virions, its small size (97 amino
acids) and the small size of the extracellular domain (23
amino acids without Met1) [8-10]. Experiments have
shown that vaccination of mice with an M2-hepatitis B
virus core (HBc) fusion protein can generate antibodies,
that after serum transfer protect against a lethal virus chal-
lenge [5]. Wu et al. found that M2e alone was a poor im-
munogen which did not elicit a significant immune
response in mice, while combined with aluminim or
Freund adjuvant the peptide was immunogenic and vac-
cination protected against lethal dose of influenza virus
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challenge [11]. Current used vaccines include peptide car-
rier conjugates [6], baculovirus expressed M2 [12], M2 fu-
sion proteins [3], multiple antigenic peptides [13], and M
DNA vaccine [14,15]. M2e conjugated influenza vaccines
have been shown to be highly immunogenic in mice, fer-
rets and rhesus monkeys and protective against homolo-
gous and heterologous challenge with influenza A virus
[6,12,13,16,17]. Most M2 vaccines have been tested in
mice while few experiments have been performed in other
species. In pigs, contrary to mice a natural host, vaccin-
ation with an M2e fusion protein has been shown to ex-
acerbate disease symptoms after challenge [18]; similar to
what was found when inactivated SIV was used in a heter-
ologous challenge model [19]. Recently it was shown that
SIV vaccine associated respiratory problems could be de-
creased when recombinant M2 was added to the vaccine.
However, again M2 alone did not reduce virus shedding
[20]. These data suggest that for each species it is neces-
sary to find out whether vaccination with M2 protein or
subunits of this protein has a potential. In chickens Nayak
et al. tested recombinant NDV vectors that expressed each
of the three surface proteins of high pathogenic AIV. They
found no indication for M2 to be immunogenic or pro-
tective [21]. Zhang et al. used a plasmid coding for an M2
protein of which the transmembrane region was deleted.
They found that chicken C3d enhanced the humoral im-
munity against AIV M2 protein, be it with a poor protec-
tion ratio [22]. In contrast, Layton et al. (2009) showed
that Salmonella vectored vaccines expressing a M2e epi-
tope in association with CD154 are effective at protecting
chickens against LPAI, but not against HPAI [23].
This article describes for the first time the use of a full
length M2 protein and synthetic M2e peptide to vaccin-
ate chickens, a natural host of avian influenza. We re-
port a study in which we vaccinated chickens with
Stimune adjuvanted full length M2 protein, M2e peptide
and Streptavidin bound M2e peptide in a tetrameric
conformation.
Results
M2 expression
The identity of the cloned genes was confirmed by PCR
and gene sequencing. A band with approximately
15 kDa was observed after induction of the His-tagged
M2, which was confirmed by Western-blot analysis
using a commercial rabbit anti-M2 antibody. After in-
duction of the MBP-tagged gene, a band with approxi-
mately 55 kDa was observed, corresponding with the
correct size of MBP (42 kDa) and M2 (15 kDa). The in-
duction of both constructs showed to be disadvanta-
geous for bacterial growth as compared to bacteria with
no construct in their plasmid. Due to the decrease of
bacterial growth after induction, the yield of M2 protein
was low (< 0.5 mg/l induced medium).
Antibody detection
To test if antibodies from the sera recognized the M2 pro-
tein, an ELISA using MBP-M2 protein was performed
(Figure 1). Antibody responses were only detected to
MBP-M2 protein after booster vaccination with full length
His-M2 protein. In the peptide immunized-groups no re-
sponse to the full length MBP-M2 protein was found in
the ELISA.
We also investigated if our vaccination provoked an
antibody response against the M2e peptide (Figure 2).
After vaccination with the full length His-M2 protein,
the M2e peptide or the HSP-tetrameric construct, no
significant antibody responses were detected to the M2e
peptide. Immunization with the M2e peptide tetrameric
construct showed a significant antibody response to M2e
peptide after booster.
To test whether the antibodies recognized AIV we
used a commercial avian influenza ELISA. In Figure 3
the Sample/Negative (S/N) ratio is depicted. When the
outcome of this ratio is above 0.5, the sample is regarded
as AI positive. As an extra control of the kit we used
sera from five control animals and five animals which
showed seroconversion in the AI Flockcheck test after
H9N2 A Chicken/Saudi Arabia/SP02525/3AAV/2000
influenza challenge. In this test none of the vaccinated
groups had a positive result. The negative control sera
showed no result above the threshold, whereas the
positive control sera showed a positive S/P ratio in
the ELISA.
Figure 1 MBP-M2 protein specific antibodies in chicken sera
obtained at the time of vaccination, three weeks after
vaccination and two weeks after booster vaccination were
determined by ELISA. The ELISA plate was coated with 0.5 μg/well
affinity purified E. coli recombinant MBP-M2 protein. Vaccination
groups are indicated on the X-axis by antigen present in the vaccine
(M2 Protein = E.coli recombinant his-tagged M2 protein; M2e
Peptide = synthetic M2e peptide, M2e Tetramer = synthetic
biotinylated M2e peptide conjugated with Streptavidin, HSP70
Tetramer = synthetic biotinylated HSP70 control peptide conjugated
with Streptavidin). Average OD 405 nm value +/− SEM from five
animals in each group is shown. * = significant difference between
indicated group and the same group before vaccination.
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The amount of M2 protein on infected cells is much
higher than the amount of this protein on virus [24,25].
We infected MDCK cells and tested whether the anti-
bodies induced by the different vaccines were able to
bind to these infected cells (Figure 4). When gated on
live cells, sera from all groups had a significant higher
amount of binding to infected cells compared to the non
infected cells. Mean fluorescence intensity (MFI) from
the non infected cells was subtracted from the MFI of
the infected cells. The same negative and positive
chicken sera were used as in the ELISA. Controls with
commercial antibodies showed that infected MDCK
expressed M2 and H9. Serum from chickens obtained
two weeks after infection with influenza showed binding
to infected MDCK. No significant statistical differences
however were found when the groups vaccinated with
His-M2 protein, M2e peptide or M2e peptide tetrameric
construct were compared to the group which got the
mock vaccine with the HSP tetrameric construct.
Discussion
The conserved nature of the influenza M2 protein
makes it a promising candidate for a universal influenza
vaccine. Most vaccine studies on M2 are performed in
mice, while the few experiments described for chicken
show variable outcome [21-23]. Our article describes for
the first time the use of a full length His-M2 protein and
an M2e peptide to vaccinate chicken.
The M2 protein is a proton channel and the integra-
tion of such a protein in the membrane might lead to
membrane leakage and loss of cell viability. In our pro-
karyotic expression system, expression of His-M2 and
MBP-M2 form led to a decrease of cell growth which
might be indicative for the bioactivity M2. Though in
low yield, as was previously described by Frace et al.
[16], we were able to produce the complete M2 protein.
His-M2 was used to investigate if the M2 protein was
immunogenic following vaccination of poultry. Apart
from the protein, we used a peptide coding for M2e. Be-
cause of the known low immunogenicity of the single
peptide we also made a more immunogenic tetrameric
construct by binding the biotinilated peptide to strep-
tavidin. As a construct control we made a mock
Figure 2 M2e peptide specific antibodies from sera obtained at
the time of vaccination, three weeks after vaccination and two
weeks after booster were determined by ELISA. The ELISA plate
was coated with 0.5 μg/well synthetic M2e peptide. Vaccination
groups are indicated on the X-axis by immunogen present in the
vaccine (M2 Protein = E. coli recombinant his-tagged M2 protein;
M2e Peptide = synthetic M2e peptide, M2e Tetramer = synthetic
biotinylated M2e peptide conjugated with Streptavidin, HSP70
Tetramer = synthetic biotinylated HSP70 control peptide conjugated
with Streptavidin). Average OD405 nm value +/− SEM from five
animals in each group is shown. * = significant difference between
indicated group and the same group before vaccination.
Figure 3 Measurement of antibodies to avian influenza in serum with the IDEXX AI Flockcheck Test (IDEXX). Vaccination groups are
indicated on the X-axis by immunogen present in the vaccine (M2 Protein = E. coli recombinant his-tagged M2 protein; M2e Peptide = synthetic
M2e peptide, M2e Tetramer = synthetic biotinylated M2e peptide conjugated with Streptavidin, HSP70 Tetramer = synthetic biotinylated HSP70
control peptide conjugated with Streptavidin). The average value of the sample-negative/positive–negative (S/P) ratio +/− SEM from five animals
in each group is shown. In addition the average value of the sample-negative/positive–negative (S/P) ratio +/− SEM from triplicates of a negative
and positive reference sample from naive and H9N2 vaccinated chickens is shown (GD Deventer, The Netherlands). The threshold value of 0.5 for
a positive S/P ratio as per manufacturer instruction is depicted as a dotted line.
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Figure 4 Antibody binding to H9N2 infected MDCK cells. (A) Representative dot plots of uninfected MDCK cells (left column), H9N2 Influenza
infected MDCK (middle column) and overlays of specific antibody responses (right panels) are depicted. Top panels shown FSC-SSC dot plots,
second line of panels indicate 7AAD live/dead discrimination in FL3 channel. Third row shows staining of live uninfected (left) and H9N2 infected
(middle) MDCK cells with rabbit-anti-M2 antibody and the respective overlay (right panel). Fourth row shows staining of live uninfected (left) and
H9N2 infected (middle) MDCK cells with rabbit-anti-HA antibody and the respective overlay (right panel). Fifth row shows staining of live
uninfected (left) and H9N2 infected (middle) MDCK cells with naïve rabbit control antibody and the respective overlay (right panel). (B)
Representative dot plots specific antibody responses of one of five vaccinated chickens to uninfected MDCK cells (left column), H9N2 Influenza
infected MDCK (middle column) and overlays of (right panels) are depicted for each indicated treatment group (top to bottom: his-M2 protein,
M2e peptide, M2e tetramer and HSP70 tetramer), followed by negative and H9N2 vaccinated positive chicken reference serum. (C) The average
value of the mean fluorescence intensity (MFI) of the H9N2 infected MDCK cells minus the MFI of the uninfected MDCK cells (as depicted in (B))
+/− SEM from five animals in each treatment group (indicated on the X-axis as M2 protein, M2e Peptide, M2e Tetramer and HSP70 Tetramer
respectively) as well as triplicates +/− SEM of a negative and positive reference sample from naive and H9N2 vaccinated chickens (GD Deventer,
The Netherlands) is shown as a Delta MFI. No significant differences between treatment groups were observed.
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construct with a non influenza related peptide derived
from a HSP70 sequence.
Sera obtained after a vaccination with the full length
His-M2 protein showed a positive reaction in our MBP-
M2 ELISA. The single M2e peptide showed not to be
immunogenic, while in tetrameric conformation it
proved to be able to induce a serum antibody response.
In our vaccinated animals no seropositivity was found
using a commercial ELISA kit, which means that anti-
bodies against the vaccines do not recognize influenza
virus as coated on the plate. It is not known how sensi-
tive this commercial test is for detecting M2-specific
antibodies. Specific chicken antisera to HA, NP and M2
were not available to address this question. It is quite
likely that the test has a higher sensitivity in detecting
other influenza specific antibodies to more abundant
influenza antigens such as HA and NP over M2.
Jegerlehner et al. and Kaiser et al. stated that M2 anti-
bodies do not bind to influenza virus nor neutralize virus
infection, but only bind to the protein on infected cells
to promote their clearance [26,27]. Since antibodies
against the M2 protein might play an important role in
directing effector cells to their targets and the amount of
M2 is much higher on infected cells than on virions, we
extended our readout from an ELISA system to a flow
cytometry based protocol with infected MDCK cells
[28]. After infection, the MDCK cells express the viral
proteins, including M2, on their surface as was shown
by fluorescent labeling. In sera from all groups, obtained
two weeks after avian influenza infection, binding to
infected cells MDCK was observed, but when compared
to the HSP group however, none of the groups showed a
significant difference. This makes binding to infected
cells not likely to be specific binding to the native tetra-
meric form of the M2 protein. Antibodies as found by
ELISA were not able to bind M2 on infected cells and
therefore recognize only the monomeric but not the
tetrameric native form of the protein.
A synthetic M2e peptide coupled to KLH [29], and
even adjuvanted synthetic M2e peptide without carrier
proteins were able to generate M2e-specific immune re-
sponses in mice [11]. Combined with the positive vac-
cination experiments in chicken [22,23] this led to the
expectation that M2 protein and M2e peptide vaccin-
ation would work in chicken as well. Our study shows
that it is possible in chicken to raise antibodies against a
bacterial expressed avian influenza M2 protein or
streptavidin bound M2e peptide in a tetrameric con-
formation. Antibodies raised to the recombinant M2
protein have a tendency to react to M2e peptide how-
ever this effect was not significant probably due to the
fact that more epitopes are present in M2 protein. Anti-
bodies generated to M2e peptide-tetramer showed lim-
ited binding in the M2 protein ELISA. The M2e epitope
density in the MBP-M2 coated ELISA system may be
limiting for M2e-peptide generated antibodies as the
MBP constitutes a 42 kD tag per M2. Though our vacci-
nations proved to be immunogenic, this did not lead to
statistically significant recognition of native M2 by
chicken serum, be it on the virus or on infected cells.
The problem with extrapolating results for M2 vaccines
from mice to other animals was shown by Fu et al. in an
experiment in which they compared the immunogenicity
of a vaccine in mice and rhesus monkeys [30]. Experi-
ments with vaccines based on M2 protein in chicken
and pig, both natural hosts of influenza, have not been
as successful as in mice, which forces us to rethink vac-
cine composition. Current poultry vaccines consist of
inactivated whole virus in oil emulsion, live attenuated
viruses, recombinant viruses or immune-complexed vi-
ruses while research focuses on the development of sub-
unit vaccines [31]. The peptide vaccines, especially the
ones based on M2e, are poorly immunogenic and need a
strong adjuvant. In poultry, so far to our knowledge no
synthetic peptide vaccines have been described. Increas-
ing immunogenicity by coupling the peptide to KLH [6]
or using cytokines as adjuvants [31] might lead to better
responses and functional vaccines.
Conclusion
Our data suggest that for each species it is necessary to
find out whether vaccination with M2 protein or sub-
units of this protein has a potential. In chickens, a nat-
ural host of avian influenza, a vaccination with the full
length M2 protein or synthetic M2e peptide in a tetra-
meric conformation proved to be immunogenic but the
induced antibodies did not recognize M2 on the virus or
on infected cells. This makes our components in their
present form not applicable as single unit vaccines, but
as an additional subunit in a vaccine containing more
peptides based on viral proteins such as HA and NA,
M2(e) might still be able to play a role in protection
against influenza viruses.
Methods
Chickens
Day-old Lohmann Brown Light layer chickens (Verbeek)
were tagged and housed with saw dust bedding in the
faculty animal housing facilities. Chicks were fed ad
libitum with free access to drinking water. The experi-
ment was carried out in accordance with the Dutch
regulation on experimental animals and approved by the
Animal Experiment Committee of Utrecht University.
M2 protein constructs
The LPAI strain: A/chicken/Italy/1067/99 (H7N1) was
used as cDNA source; kind gift of Dr I. Capua (Istituto
Zooprofilattico Sperimentale delle Venezie, Italy). The M2
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gene is the product of a spliced M gene. M2 (aa10-97)
sequence lacking the first 26 basepairs was cloned this
cDNA into a Pet100 plasmid (Invitrogen). With an elon-
gated primer complete M2 was cloned into a Pet100 plas-
mid. For MBP-M2 protein expression, complete M2 with
restriction sites for EcoRV and BamHI was cloned into the
pMAL-p5X vector (New England Biolabs). All primers are
displayed in Table 1. Identity of cDNA and cloned PCR
products were checked by sequencing.
Expression of recombinant M2 proteins
Complete M2 constructs were transformed into BL21
Star (DE3) One Shot cells (Invitrogen).
Cells containing Pet100 plasmid were grown in LB
Broth containing 100 μg/ml ampicillin. Expression of
His-M2 was induced for four hours using 0.05 mM
isopropythio b-D-galactosidase (IPTG). Recombinant
His-M2 protein was extracted from inclusion bodies and
purified with the probond (Ni)-chelating resin column
according the denaturating protocol provided by the
manufacturer (Invitrogen).
Cells containing the pMAL-p5X plasmid were grown
in LB Broth with 100 ug/ml ampicillin and 2.0 g glu-
cose/l. Expression of MBP-M2 was induced for four
hours using 0.3 mM IPTG. Maltose-binding protein
(MBP) purification was performed with the Amylose
resin column according to the total cell extract protocol
provided by the manufacturer (New England Biolabs).
Electrophoresis and Western blot analysis
Proteins (0.1–1.0 μg/lane) were analyzed by SDS-PAGE
using 10% polyacrylamide gels. Protein bands were visual-
ized by Gelcode Blue Stain reagent (Thermo Scientific).
Proteins (0.1–1.0 μg/lane) were transferred electrophoret-
ically from the gels onto nitrocellulose membrane and im-
munostained using rabbit anti-M2e (Immune Technology
Corp.) followed by alkaline phosphatase-conjugated mouse
anti-rabbit immunoglobulin G (IgG) (Sigma).
Peptides and tetramers
A synthetic M2e peptide composed of amino acids 1–
24, with an additional biotinylated C-terminal lysine
(sequence: MSLLTEVETPTRNGWECKCSDSSDK-biotin)
was obtained from GenScript (Genscript). To increase
immunogenicity of this M2e peptide, a tetramer was
constructed by adding the peptide to streptavidin
(Applichem) in an 8:1 molecular ratio for an hour at room
temperature. Unbound peptide was removed by centrifu-
gation over a 30,000 kD Vivaspin 500 Filter (Sartorius).
A peptide representing a linear B cell epitope of the
Mycobacterium avium subspecies paratuberculosis (MAP)
HSP70 protein (sequence: CITDAVITVPAYFND-biotin)
was used as a control [32].
Immunization
20 chickens were divided into four groups of five ani-
mals. At day 21 of age animals were immunized in the
breast muscle with a BD Plastipak syringe with a 0.45 ×
10 mm needle (BD) with 150 μl of His-M2 protein vac-
cine or 100 μl of the other vaccines. A homologous
booster immunization was given at day 42 of age. Group
1 received the subunit vaccine of 200 μg His-M2 protein.
Group 2 received 40 μg of the M2e peptide. Group 3 re-
ceived a vaccine consisting of the M2e-streptavidine
tetrameric construct containing 40 μg M2e. Group 4 re-
ceived a vaccine consisting of the HSP-streptavidin tetra-
meric construct containing 20 μg HSP-peptide. All
vaccines were adjuvanted with Stimune (Prionics), four
parts of the water phase containing the antigen were
mixed with five parts Stimune (v/v). The amount of mol-
ecules present in 200 μg His-M2 protein was calculated
and the amount of peptide molecules injected in groups
2, 3 and 4 was adjusted to match this amount.
Serum samples were taken before immunization, three
weeks after vaccination and two weeks after booster
(resp. day 21, 42 and 56 of age) by vene puncture of the
wingweb vene. Chickens were sacrificed by cervical dis-
location at 56 days of age; serum was collected, and
stored at −20°C until analyzed.
Antibody detection
Antibodies to the whole M2 protein or M2e peptide
were detected by an indirect ELISA test. 96-wells plates
were coated with 0.5 μg/well MBP-M2 protein or M2e
peptide in pH 9.6 bicarbonate buffer (100 μl). Plates
were blocked with 200 μl ELISA blocking buffer (Roche
Diagnostic GmbH). After each incubation step, plates
were washed three times with PBS-0.01% Tween20.
Incubations were performed for 20 min at 37°C.
Plates were incubated with 1:10 diluted chicken serum
in PBS-0.05% Tween20, mouse anti chicken IgL (1:1000)
(Southern Biotechnology), goat anti mouse-Ig-AP (1:1000)
(DAKO) and p-nitrophenyl phosphate (PNPP) substrate
(Pierce). The OD was measured using a Biorad microplate
reader at 405 nm. Samples were corrected for background
signal.
Table 1 Primers used to amplify the M2 sequences
Primer name Primer sequence
M2(aa10-97) F CACCTACCAGAAACGGATGGGAGTGCAAA
M2(aa10-97) R TTACTCCAGCTCTATGTTGACAAA
M2(aa1-97) F CACCATGAGTCTTCTAACCGAGGTCG
AAACGCCTACCAGAAACGGATGGG
M2(aa1-97) R TTACTCCAGCTCTATGTTGACAAAATG
M2 pMal F EcoRV GATATCAGTCTTCTAACCGAGGTCGAAACGCCT
M2 pMal R BamHI GGATCCTTACTCCAGCTCTATGTTGACAA
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Antibodies recognizing virus were detected using the
AI Flockcheck test (IDEXX) according to the manual of
the manufacturer.
In vitro infection of MDCK cells
We infected MDCK cells to test whether serum from
vaccinated animals could bind native M2. Twenty-four
-well plates were seeded with 5 × 105 MDCK cells per
well. At 80% confluence, cells were infected (or left un-
infected as a control) with 200 μl infection medium
(DMEM + Glutamax + 0.1% BSA) with 106 egg infective
doses (EID50) of H9N2 A/Chicken/Saudi Arabia/
SP02525/3AAV/2000 per ml. Plates were incubated at
37°C for 1 h and non-bound virus was washed away with
PBS. Cells were cultured overnight at 37°C in infection
medium with 1.0 μg/ml trypsine (Wortington). After
washing with PBS and adding 5.0 mM EDTA single cells
were obtained and pooled. Pool samples were taken for
flow cytometry.
Flow cytometry
Cells were stained for 30 min with Chicken serum
obtained from animals at 56 days of age, five times diluted
in PBA (PBS with 0.5% BSA and 0.005% NaN3), mouse
anti-chicken IgL (1:100)_(Southern Biotech) and goat
anti-mouse FITC (1:100) (Southern Biotech). Positive con-
trols were cells stained with rabbit polyclonal anti-M2
(1:100) or rabbit anti-HA1 (1:100) (Immune Technology
Corp.) followed by donkey anti-rabbit IgG Alexa Fluor
488 (1:100) (Invitrogen); chicken anti H9N2 antiserum
(1:100) (H9N2 positive chicken reference serum obtained
from GD Veterinary Health Service, Deventer, The
Netherlands) followed with mouse anti-chicken IgL
(1:100)_(Southern Biotech). As conjugate controls, rabbit
pre-immune serum (Immune Technology Corp.) and
negative chicken serum were used.
2.0 μl 7-Aminoactinomycin D (7-AAD) was added to all
samples and after 1 min cells were washed and fixed in 2%
paraformaldehyde. A total of at least 20,000 events was ac-
quired using a FACScan flowcytometer (BD) and data
were analysed using the FlowJO software (Threestar Inc.).
Statistics
Data were analysed with ANOVA using Graphpad Prism.
If variances were not equal data were log transformed or a
Kruskal-Wallis test was performed. A Bonferroni or Dunn
post hoc test was used and the level of significance was set
at p < 0.05.
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